430 related articles for article (PubMed ID: 25713363)
21. Chromatin modifying gene mutations in follicular lymphoma.
Green MR
Blood; 2018 Feb; 131(6):595-604. PubMed ID: 29158360
[TBL] [Abstract][Full Text] [Related]
22. KMT2D acetylation by CREBBP reveals a cooperative functional interaction at enhancers in normal and malignant germinal center B cells.
Vlasevska S; Garcia-Ibanez L; Duval R; Holmes AB; Jahan R; Cai B; Kim A; Mo T; Basso K; Soni RK; Bhagat G; Dalla-Favera R; Pasqualucci L
Proc Natl Acad Sci U S A; 2023 Mar; 120(11):e2218330120. PubMed ID: 36893259
[TBL] [Abstract][Full Text] [Related]
23. CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas.
Jiang Y; Ortega-Molina A; Geng H; Ying HY; Hatzi K; Parsa S; McNally D; Wang L; Doane AS; Agirre X; Teater M; Meydan C; Li Z; Poloway D; Wang S; Ennishi D; Scott DW; Stengel KR; Kranz JE; Holson E; Sharma S; Young JW; Chu CS; Roeder RG; Shaknovich R; Hiebert SW; Gascoyne RD; Tam W; Elemento O; Wendel HG; Melnick AM
Cancer Discov; 2017 Jan; 7(1):38-53. PubMed ID: 27733359
[TBL] [Abstract][Full Text] [Related]
24. Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression.
Han G; Deng Q; Marques-Piubelli ML; Dai E; Dang M; Ma MCJ; Li X; Yang H; Henderson J; Kudryashova O; Meerson M; Isaev S; Kotlov N; Nomie KJ; Bagaev A; Parra ER; Solis Soto LM; Parmar S; Hagemeister FB; Ahmed S; Iyer SP; Samaniego F; Steiner R; Fayad L; Lee H; Fowler NH; Flowers CR; Strati P; Westin JR; Neelapu SS; Nastoupil LJ; Vega F; Wang L; Green MR
Blood Cancer Discov; 2022 Sep; 3(5):428-443. PubMed ID: 35687817
[TBL] [Abstract][Full Text] [Related]
25. Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303.
Russler-Germain DA; Krysiak K; Ramirez C; Mosior M; Watkins MP; Gomez F; Skidmore ZL; Trani L; Gao F; Geyer S; Cashen AF; Mehta-Shah N; Kahl BS; Bartlett NL; Alderuccio JP; Lossos IS; Ondrejka SL; Hsi ED; Martin P; Leonard JP; Griffith M; Griffith OL; Fehniger TA
Blood Adv; 2023 Sep; 7(18):5524-5539. PubMed ID: 37493986
[TBL] [Abstract][Full Text] [Related]
26. Tumor suppressors in follicular lymphoma.
Graham C; LeBrun DP
Leuk Lymphoma; 2015 Jul; 56(7):1981-8. PubMed ID: 25379618
[TBL] [Abstract][Full Text] [Related]
27. Genomic and epigenomic co-evolution in follicular lymphomas.
Loeffler M; Kreuz M; Haake A; Hasenclever D; Trautmann H; Arnold C; Winter K; Koch K; Klapper W; Scholtysik R; Rosolowski M; Hoffmann S; Ammerpohl O; Szczepanowski M; Herrmann D; Küppers R; Pott C; Siebert R;
Leukemia; 2015 Feb; 29(2):456-63. PubMed ID: 25027518
[TBL] [Abstract][Full Text] [Related]
28. Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease.
Nann D; Ramis-Zaldivar JE; Müller I; Gonzalez-Farre B; Schmidt J; Egan C; Salmeron-Villalobos J; Clot G; Mattern S; Otto F; Mankel B; Colomer D; Balagué O; Szablewski V; Lome-Maldonado C; Leoncini L; Dojcinov S; Chott A; Copie-Bergman C; Bonzheim I; Fend F; Jaffe ES; Campo E; Salaverria I; Quintanilla-Martinez L
Blood Adv; 2020 Nov; 4(22):5652-5665. PubMed ID: 33211828
[TBL] [Abstract][Full Text] [Related]
29. Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma.
Bouska A; Zhang W; Gong Q; Iqbal J; Scuto A; Vose J; Ludvigsen M; Fu K; Weisenburger DD; Greiner TC; Gascoyne RD; Rosenwald A; Ott G; Campo E; Rimsza LM; Delabie J; Jaffe ES; Braziel RM; Connors JM; Wu CI; Staudt LM; D'Amore F; McKeithan TW; Chan WC
Leukemia; 2017 Jan; 31(1):83-91. PubMed ID: 27389057
[TBL] [Abstract][Full Text] [Related]
30. Mass Cytometry of Follicular Lymphoma Tumors Reveals Intrinsic Heterogeneity in Proteins Including HLA-DR and a Deficit in Nonmalignant Plasmablast and Germinal Center B-Cell Populations.
Wogsland CE; Greenplate AR; Kolstad A; Myklebust JH; Irish JM; Huse K
Cytometry B Clin Cytom; 2017 Jan; 92(1):79-87. PubMed ID: 27933753
[TBL] [Abstract][Full Text] [Related]
31. Follicular lymphoma, a B cell malignancy addicted to epigenetic mutations.
Korfi K; Ali S; Heward JA; Fitzgibbon J
Epigenetics; 2017 May; 12(5):370-377. PubMed ID: 28106467
[TBL] [Abstract][Full Text] [Related]
32. New concepts in follicular lymphoma biology: From BCL2 to epigenetic regulators and non-coding RNAs.
Devan J; Janikova A; Mraz M
Semin Oncol; 2018 Oct; 45(5-6):291-302. PubMed ID: 30360879
[TBL] [Abstract][Full Text] [Related]
33. Re-entry of tumour B cells into the cycle of somatic mutation and isotype switching in follicular lymphoma.
Shiokawa S; Matsushima T; Choi I; Abe Y; Shiratsuchi M; Suehiro Y; Muta K; Ohshima K; Nishimura J
Br J Haematol; 2003 Feb; 120(3):492-5. PubMed ID: 12580967
[TBL] [Abstract][Full Text] [Related]
34. DNA-mediated transfer of major histocompatibility class II I-Ab and I-Abm12 genes into B lymphoma cells: molecular and functional analysis of introduced antigens.
Ben-Nun A; Choi E; McIntyre KR; Leeman SA; McKean DJ; Seidman JG; Glimcher LH
J Immunol; 1985 Aug; 135(2):1456-64. PubMed ID: 3925010
[TBL] [Abstract][Full Text] [Related]
35. B-Lymphoblastic Lymphomas Evolving from Follicular Lymphomas Co-Express Surrogate Light Chains and Mutated Gamma Heavy Chains.
Slot LM; Hoogeboom R; Smit LA; Wormhoudt TA; Biemond BJ; Oud ME; Schilder-Tol EJ; Mulder AB; Jongejan A; van Kampen AH; Kluin PM; Guikema JE; Bende RJ; van Noesel CJ
Am J Pathol; 2016 Dec; 186(12):3273-3284. PubMed ID: 27750045
[TBL] [Abstract][Full Text] [Related]
36. Follicular lymphoma B cells exhibit heterogeneous transcriptional states with associated somatic alterations and tumor microenvironments.
Krull JE; Wenzl K; Hopper MA; Manske MK; Sarangi V; Maurer MJ; Larson MC; Mondello P; Yang Z; Novak JP; Serres M; Whitaker KR; Villasboas Bisneto JC; Habermann TM; Witzig TE; Link BK; Rimsza LM; King RL; Ansell SM; Cerhan JR; Novak AJ
Cell Rep Med; 2024 Mar; 5(3):101443. PubMed ID: 38428430
[TBL] [Abstract][Full Text] [Related]
37. The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytes.
Thompson JA; Srivastava MK; Bosch JJ; Clements VK; Ksander BR; Ostrand-Rosenberg S
Cancer Immunol Immunother; 2008 Mar; 57(3):389-98. PubMed ID: 17724589
[TBL] [Abstract][Full Text] [Related]
38. Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen Inhibits Major Histocompatibility Complex Class II Expression by Disrupting Enhanceosome Assembly through Binding with the Regulatory Factor X Complex.
Thakker S; Purushothaman P; Gupta N; Challa S; Cai Q; Verma SC
J Virol; 2015 May; 89(10):5536-56. PubMed ID: 25740990
[TBL] [Abstract][Full Text] [Related]
39. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.
Schirrmacher V; Schild HJ; Gückel B; von Hoegen P
Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():311-26. PubMed ID: 7901150
[TBL] [Abstract][Full Text] [Related]
40. Development of autologous cytotoxic CD4+ T clones in a human model of B-cell non-Hodgkin follicular lymphoma.
Mi JQ; Manches O; Wang J; Perron P; Weisbuch S; Marche PN; Renversez JC; Bensa JC; Sotto JJ; Cahn JY; Leroux D; Bonnefoix T
Br J Haematol; 2006 Nov; 135(3):324-35. PubMed ID: 16984392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
